New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 25, 2014
14:02 EDTCNCEConcert Pharm says phase 2 trial of CTP-499 did not meet primary endpoint
News For CNCE From The Last 14 Days
Check below for free stories on CNCE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 16, 2014
07:00 EDTCNCEConcert Pharmaceuticals says FDA lifts partial clinical hold for CTP-354
Concert Pharmaceuticals announced that the FDA has provided notification that the company has completed the necessary preclinical toxicology testing in order to administer repeated doses of CTP-354 in excess of 6 mg per day, lifting its partial clinical hold. As a result, the company intends to initiate dosing of 12 mg per day of CTP-354 in the third quarter of this year as part of its ongoing multiple ascending dose Phase 1 trial. Concert is initially developing CTP-354 for use in patients with spinal cord injury and in patients with multiple sclerosis to address significant unmet medical needs.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use